Inhibitors of DNA methyltransferases: Insights from computational studies

Current Medicinal Chemistry

Volumn 19, Issue 21, 2012, Pages 3475-3487

  Yoo, J ^a   Medina Franco, J L ^a  

^a TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

Author keywords

Cancer; Docking; Drug discovery; Enzyme inhibitor; Epigenetics; Homology modeling; Molecular dynamics; Natural products; Structure activity relationships; Virtual screening

Indexed keywords

2 ISOXAZOLINE DERIVATIVE; 5 AZA 2' DEOXYCYTIDINE; 5,5' METHYLENEDISALICYLIC ACID; AZACITIDINE; CURCUMIN; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3B; DNA METHYLTRANSFERASE INHIBITOR; EPIGALLOCATECHIN GALLATE; HYDRALAZINE; MAHANINE; MITRAMYCIN A; N PHTHALOYLTRYPTOPHAN; NANAOMYCIN A; NSC 14778; NSC 97317; PARTHENOLIDE; PROCAINAMIDE; PROCAINE; TRIMETHYLAURINTRICARBOXYLIC ACID; UNCLASSIFIED DRUG; ZEBULARINE;

AMINO ACID SEQUENCE; CRYSTAL STRUCTURE; DNA METHYLATION; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; HYDROGEN BOND; MOLECULAR DOCKING; MOLECULAR DYNAMICS; PHARMACOPHORE; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 84863731355     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712801323289     Document Type: Review

References (84)

1. Foulks, J.M.; Parnell, K.M.; Nix, R.N.; Chau, S.; Swierczek, K.; Saunders, M.; Wright, K.; Hendrickson, T.F.; Ho, K.-K.; McCullar, M.V.; Kanner, S.B. Epigenetic drug discovery. J. Biomol. Screening, 2012, 17, 2-17.
2. Martinet, N.; Michel, B.Y.; Bertrand, P.; Benhida, R. Small molecules DNA methyltransferases inhibitors. MedChemComm, 2012, 3, 263-273.
3. Robertson, K.D. DNA methylation, methyltransferases, and cancer. Oncogene, 2001, 20, 3139-3155.
4. Chen, T.P.; Hevi, S.; Gay, F.; Tsujimoto, N.; He, T.; Zhang, B.L.; Ueda, Y.; Li, E. Complete inactivation of DNMT1 leads to mitotic catastrophe in human cancer cells. Nat. Genet., 2007, 39, 391-396.
5. Cheng, X.D.; Blumenthal, R.M. Mammalian DNA methyltransferases: A structural perspective. Structure, 2008, 16, 341-350.
6. Schaefer, M.; Lyko, F. Solving the Dnmt2 enigma. Chromosoma, 2010, 119, 35-40.
7. Jones, P.A.; Baylin, S.B. The epigenomics of cancer. Cell, 2007, 128, 683-692.
8. Lyko, F.; Brown, R. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J. Natl. Cancer Inst., 2005, 97, 1498-1506.
9. Portela, A.; Esteller, M. Epigenetic modifications and human disease. Nat. Biotechnol., 2010, 28, 1057-1068.
10. Kelly, T.K.; De Carvalho, D.D.; Jones, P.A. Epigenetic modifications as therapeutic targets. Nat. Biotechnol., 2010, 28, 1069-1078.
11. Jurkowska, R.Z.; Jurkowski, T.P.; Jeltsch, A. Structure and function of mammalian DNA methyltransferases. ChemBioChem, 2011, 12, 206-222.
12. Jeltsch, A. Beyond watson and crick: DNA methylation and molecular enzymology of DNA methyltransferases. ChemBioChem, 2002, 3, 274-293.
13. Lan, J.; Hua, S.; He, X.N.; Zhang, Y. DNA methyltransferases and methyl-binding proteins of mammals. Acta Biochim. Biophys. Sin., 2010, 42, 243-252.
14. Song, J.; Rechkoblit, O.; Bestor, T.H.; Patel, D.J. Structure of DNMT1-DNA complex reveals a role for autoinhibition in maintenance DNA methylation. Science, 2011, 331, 1036-1040.
15. Takeshita, K.; Suetake, I.; Yamashita, E.; Suga, M.; Narita, H.; Nakagawa, A.; Tajima, S. Structural insight into maintenance methylation by mouse DNA methyltransferase 1 (Dnmt1). Proc. Natl. Acad. Sci. U. S. A., 2011, 108, 9055-9059.
16. Syeda, F.; Fagan, R.L.; Wean, M.; Avvakumov, G.V.; Walker, J.R.; Xue, S.; Dhe-Paganon, S.; Brenner, C. The replication focus targeting sequence (RFTS) domain is a DNA-competitive inhibitor of dnmt1. J. Biol. Chem., 2011, 286, 15344-15351.
17. Klimasauskas, S.; Kumar, S.; Roberts, R.J.; Cheng, X.D. HhaI methyltransferase flips its target base out of the DNA helix. Cell, 1994, 76, 357-369.
18. Kumar, S.; Horton, J.R.; Jones, G.D.; Walker, R.T.; Roberts, R.J.; Cheng, X. DNA containing 4'-thio-2'-deoxycytidine inhibits methylation by HhaI methyltransferase. Nucleic Acids Res., 1997, 25, 2773-2783.
19. Sheikhnejad, G.; Brank, A.; Christman, J.K.; Goddard, A.; Alvarez, E.; Ford, H.; Marquez, V.E.; Marasco, C.J.; Sufrin, J.R.; O'Gara, M.; Cheng, X.D. Mechanism of inhibition of DNA (cytosine C5)-methyltransferases by oligodeoxyribonucleotides containing 5, 6-dihydro-5-azacytosine. J. Mol. Biol., 1999, 285, 2021-2034.
20. Zhou, L.; Cheng, X.; Connolly, B.A.; Dickman, M.J.; Hurd, P.J.; Hornby, D.P. Zebularine: A novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. J. Mol. Biol., 2002, 321, 591-599.
21. Reinisch, K.M.; Chen, L.; Verdine, G.L.; Lipscomb, W.N. The crystal-structure of HaeIII methyltransferase covalently complexed to DNA-an extrahelical cytosine and rearranged base-pairing. Cell, 1995, 82, 143-153.
22. Dong, A.P.; Yoder, J.A.; Zhang, X.; Zhou, L.; Bestor, T.H.; Cheng, X.D. Structure of human DNMTT2, an enigmatic DNA methyltransferase homolog that displays denaturant-resistant binding to DNA. Nucleic Acids Res., 2001, 29, 439-448.
23. Wu, H.; Zeng, H.; Lam, R.; Tempel, W.; Amaya, M.F.; Xu, C.; Dombrovski, L.; Qiu, W.; Wang, Y.; Min, J. Structural and histone binding ability characterizations of human PWWP domains. Plos One, 2011, 6, e18919.
24. Otani, J.; Nankumo, T.; Arita, K.; Inamoto, S.; Ariyoshi, M.; Shirakawa, M. Structural basis for recognition of H3K4 methylation status by the DNA methyltransferase 3A ATRX-DNMT3-DNMT3L domain. EMBO Reports, 2009, 10, 1235-1241.
25. Ooi, S.K.T.; Qiu, C.; Bernstein, E.; Li, K.Q.; Jia, D.; Yang, Z.; Erdjument-Bromage, H.; Tempst, P.; Lin, S.P.; Allis, C.D.; Cheng, X.D.; Bestor, T.H. DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature, 2007, 448, 714-U713.
26. Jia, D.; Jurkowska, R.Z.; Zhang, X.; Jeltsch, A.; Cheng, X. Structure of Dnmt3a bound to Dnmt3L suggests a model for de novo DNA methylation. Nature, 2007, 449, 248-251.
27. Sippl, W.; Jung, M. DNA methyltransferase inhibitors. In Epigenetic Targets in Drug Discovery, Sippl, W.; Jung, M. Eds.; Wiley-VCH: Weinheim, 2009. pp. 163-183.
28. Stresemann, C.; Lyko, F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int. J. Cancer, 2008, 123, 8-13.
29. Schermelleh, L.; Spada, F.; Easwaran, H.P.; Zolghadr, K.; Margot, J.B.; Cardoso, M.C.; Leonhardt, H. Trapped in action: Direct visualization of DNA methyltransferase activity in living cells. Nat. Methods, 2005, 2, 751-756.
30. Issa, J.P.J.; Kantarjian, H.M.; Kirkpatrick, P. Azacitidine. Nat. Rev. Drug Discovery, 2005, 4, 275-276.
31. Schrump, D.S.; Fischette, M.R.; Nguyen, D.M.; Zhao, M.; Li, X.M.; Kunst, T.F.; Hancox, A.; Hong, J.A.; Chen, G.A.; Pishchik, V.; Figg, W.D.; Murgo, A.J.; Steinberg, S.M. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin. Cancer Res., 2006, 12, 5777-5785.
32. Issa, J.-P.J.; Kantarjian, H.M. Targeting DNA methylation. Clin. Cancer Res., 2009, 15, 3938-3946.
33. Belinsky, S.A.; Klinge, D.M.; Stidley, CA.; Issa, J.P.; Herman, J.G.; March, T.H.; Baylin, S.B. Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res., 2003, 63, 7089-7093.
34. Issa, J.-P. Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: Dose, duration, and patient selection. Nat. Clin. Pract. Oncol, 2005, 2 Suppl 1, S24-29.
35. Fandy, T.E.; Herman, J.G.; Kerns, P.; Jiemjit, A.; Sugar, E.A.; Choi, S.H.; Yang, A.S.; Aucott, T.; Dauses, T.; Odchimar-Reissig, R.; Licht, J.; McConnell, M.J.; Nasrallah, C; Kim, M.K.H.; Zhang, W.J.; Sun, Y.Z.; Murgo, A.; Espinoza-Delgado, I; Oteiza, K.; Owoeye, I; Silverman, L.R.; Gore, S.D.; Carraway, H.E. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood, 2009, 114, 2764-2773.
36. Palii, S.S.; Van Emburgh, B.O.; Sankpal, U.T.; Brown, K.D.; Robertson, K.D. DNA methylation inhibitor 5-aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol. Cell. Biol, 2008, 28, 752-771.
37. Suzuki, T.; Tanaka, R.; Hamada, S.; Nakagawa, H.; Miyata, N. Design, synthesis, inhibitory activity, and binding mode study of novel DNA methyltransf erase 1 inhibitors. Bioorg. Med. Chem. Lett, 2010, 20, 1124-1127.
38. Yu, N; Wang, M. Anticancer drug discovery targeting DNA hypermethylation. Curr. Med. Chem., 2008, 15, 1350-1375.
39. Hauser, A.T.; Jung, M. Targeting epigenetic mechanisms: Potential of natural products in cancer chemoprevention. Planta Med, 2008, 74, 1593-1601.
40. Castellano, S.; Kuck, D.; Viviano, M.; Yoo, J.; López-Vallejo, F.; Conti, P; Tamborini, L.; Pinto, A.; Medina-Franco, J.L.; Sbardella, G. Synthesis and biochemical evaluation of A-isoxazoline derivatives as DNA methyltransf erase 1 inhibitors. J. Med. Chem., 2011, 54, 7663-7677.
41. Segura-Pacheco, B.; Trejo-Becerril, C; Perez-Cardenas, E.; Taja-Chayeb, L.; Mariscal, I; Chavez, A.; Acuna, C; Salazar, A.M.; Lizano, M.; Duenas-Gonzalez, A. Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. Clin. Cancer Res., 2003, 9, 1596-1603.
42. Villar-Garea, A.; Fraga, M.F.; Espada, J.; Esteller, M. Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. Cancer Res., 2003, 63, 4984-4989.
43. Lee, B.H.; Yegnasubramanian, S.; Lin, X.H.; Nelson, W.G. Procainamide is a specific inhibitor of DNA methyltransf erase 1. J. Biol. Chem., 2005, 280, 40749-40756.
44. Siedlecki, P.; Boy, R.G.; Musch, T; Brueckner, B.; Suhai, S.; Lyko, F.; Zielenkiewicz, P. Discovery of two novel, small-molecule inhibitors of DNA methylation. J. Med. Chem., 2006, 49, 678-683.
45. Kuck, D.; Singh, N; Lyko, F; Medina-Franco, J.L. Novel and selective DNA methyltransf erase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg. Med. Chem., 2010, 18, 822-829.
46. Gilbert, E.R.; Liu, D. Flavonoids influence epigenetic-modifying enzyme activity: Structure-function relationships and the therapeutic potential for cancer. Curr. Med. Chem., 2010, 17, 1756-1768.
47. Li, Y; Tollefsbol, T.O. Impact on DNA methylation in cancer prevention and therapy by bioactive dietary components. Curr. Med. Chem., 2010, 17, 2141-2151.
48. Medina-Franco, J.L.; Caulfield, T. Advances in the computational development of DNA methyltransf erase inhibitors. Drug Discovery Today, 2011, 16, 418-425.
49. Huang, Y.-W.; Kuo, C.-T; Stoner, K.; Huang, T.H.Y; Wang, L.-S. An overview of epigenetics and chemoprevention. FEB S Lett, 2011, 585, 2129-2136.
50. Fang, M.Z.; Wang, Y.M.; Ai, N; Hou, Z.; Sun, Y; Lu, H.; Welsh, W.; Yang, CS. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransf erase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res., 2003, 63, 7563-7570.
51. Lee, W.J.; Shim, J.Y; Zhu, B.T. Mechanisms for the inhibition of DNA methyltransf erases by tea catechins and bioflavonoids. Mol Pharmacol, 2005, 68, 1018-1030.
52. Liu, Z.F.; Xie, Z.L.; Jones, W.; Pavlovicz, R.E.; Liu, S.J.; Yu, J.H.; Li, PK.; Lin, J.Y; Fuchs, J.R.; Marcucci, G.; Li, C.L.; Chan, K.K. Curcumin is a potent DNA hypomethylation agent. Bioorg. Med. Chem. Lett, 2009, 19, 706-709.
53. Medina-Franco, J.; López-Vallejo, F.; Kuck, D.; Lyko, F. Natural products as DNA methyltransf erase inhibitors: A computer-aided discovery approach. Mol Diversity, 2011, 15, 293-304.
54. Jagadeesh, S.; Sinha, S.; Pal, B.C.; Bhattacharya, S.; Banerjee, P.P. Mahanine reverses an epigenetically silenced tumor suppressor gene RASSF1A in human prostate cancer cells. Biochem. Biophys. Res. Commun., 2007, 362, 212-217.
55. Sheikh, K.D.; Banerjee, P.P.; Jagadeesh, S.; Grindrod, S.C.; Zhang, L.; Paige, M.; Brown, M.L. Fluorescent epigenetic small molecule induces expression of the tumor suppressor Ras-association domain family 1A and inhibits human prostate xenograft. J. Med. Chem., 2010, 53, 2376-2382.
56. Kuck, D.; Caulfield, T.; Lyko, F.; Medina-Franco, J.L. Nanaomycin a selectively inhibits DNMT3B and reactivates silenced tumor suppressor genes in human cancer cells. Mol. Cancer Ther., 2010, 9, 3015-3023.
57. Tang, M.Q.; Xu, W.; Wang, Q.Z.; Xiao, W.D.; Xu, R.A. Potential of DNMT and its epigenetic regulation for lung cancer therapy. Current Genomics, 2009, 10, 336-352.
58. Medina-Franco, J.L.; Lopez-Vallejo, F.; Castillo, R. Diseño de fármacos asistido por computadora. Educ. Quím. 2006, 17, 452-457.
59. Ooms, F. Molecular modeling and computer aided drug design. Examples of their applications in medicinal chemistry. Curr. Med. Chem., 2000, 7, 141-158.
60. Jorgensen, W.L. Efficient drug lead discovery and optimization. Acc. Chem. Res., 2009, 42, 724-733.
61. Heinke, R.; Carlino, L.; Kannan, S.; Jung, M.; Sippl, W. Computer-and structure-based lead design for epigenetic targets. Bioorg. Med. Chem., 2011, 19, 3605-3615.
62. Grant, M.A. Protein structure prediction in structure-based ligand design and virtual screening. Comb. Chem. High Throughput Screening, 2009, 12, 940-960.
63. Villoutreix, B.O.; Eudes, R.; Miteva, M.A. Structure-based virtual ligand screening: Recent success stories. Comb. Chem. High Throughput Screening, 2009, 12, 1000-1016.
64. Siedlecki, P.; Boy, R.G.; Comagic, S.; Schirrmacher, R.; Wiessler, M.; Zielenkiewicz, P.; Suhai, S.; Lyko, F. Establishment and functional validation of a structural homology model for human DNA methyltransferase 1. Biochem. Biophys. Res. Commun., 2003, 306, 558-563.
65. Kumar, S.; Cheng, X.D.; Klimasauskas, S.; Mi, S.; Posfai, J.; Roberts, R.J.; Wilson, G.G. The DNA (cytosine-5) methyltransferases. Nucleic Acids Res., 1994, 22, 1-10.
66. Singh, N.; Dueñas-González, A.; Lyko, F.; Medina-Franco, J.L. Molecular modeling and dynamics studies of hydralazine with human DNA methyltransferase 1. ChemMedChem, 2009, 4, 792-799.
67. Liu, Z.F.; Liu, S.J.; Xie, Z.L.; Pavlovicz, R.E.; Wu, J.; Chen, P.; Aimiuwu, J.; Pang, J.X.; Bhasin, D.; Neviani, P.; Fuchs, J.R.; Plass, C.; Li, P.K.; Li, C.; Huang, T.H.M.; Wu, L.C.; Rush, L.; Wang, H.Y.; Perrotti, D.; Marcucci, G.; Chan, K.K. Modulation of DNA methylation by a sesquiterpene lactone parthenolide. J. Pharmacol. Exp. Ther., 2009, 329, 505-514.
68. Yoo, J.; Medina-Franco, J.L. Homology modeling, docking, and structure-based pharmacophore of inhibitors of DNA methyltransferase. J. Comp.-Aided Mol. Des., 2011, 25, 555-567.
69. Yoo, J.; Medina-Franco, J.L. Trimethylaurintricarboxylic acid inhibits human DNA methyltransferase 1: Insights from enzymatic and molecular modeling studies. J. Mol. Model., 2012, 18, 1583-1589.
70. Yoo, J.; Kim, J.H.; Robertson, K.D.; Medina-Franco, J.L. Molecular Modeling of Inhibitors of Human DNA Methyltransferase with a Crystal Structure: Discovery of a Novel DNMT1 inhibitor. In Advances in Protein Chemistry and Structural biology; Structural and Mechanistic Enzymology: Bringing Computations and Experiments Together. Christov, C.; Karabencheva-Christova, T., Eds.; Elsevier, 2012, 87, pp 219-247.
71. Yoo, J.; Medina-Franco, J.L. Discovery and Optimization of Inhibitors of DNA Methyltransferase as Novel Drugs for Cancer Therapy. In Drug Development-A Case Study Based Insight Into Modern Strategies. Rundfeldt, C., Ed.; InTech, 2011, pp ISBN: 978-953-307-257-979, InTech, 2011. Available at http://www.intechopen.com/articles/show/title/discovery-and-optimization-of- inhibitors-of-dna-methyltransferase-as-novel-drugs-for-cancer-therapy
72. Langer, T. Pharmacophores in drug research. Mol. Inf., 2010, 29, 470-475.
73. Eckert, H.; Bajorath, J. Molecular similarity analysis in virtual screening: Foundations, limitations and novel approaches. Drug Discovery Today, 2007, 12, 225-233.
74. Salam, N.K.; Nuti, R.; Sherman, W. Novel method for generating structure-based pharmacophores using energetic analysis. J. Chem. Inf. Model., 2009, 49, 2356-2368.
75. Evans, D.A.; Bronowska, A.K. Implications of fast-time scale dynamics of human DNA/RNA cytosine methyltransferases (DNMTs) for protein function. Theor. Chem. Acc., 2010, 125, 407-418.
76. López-Vallejo, F.; Caulfield, T.; Martínez-Mayorga, K.; Giulianotti, M.A.; Nefzi, A.; Houghten, R.A.; Medina-Franco, J.L. Integrating virtual screening and combinatorial chemistry for accelerated drug discovery. Comb. Chem. High Throughput Screening, 2011, 14, 475-487.
77. Shoichet, B.K. Virtual screening of chemical libraries. Nature, 2004, 432, 862-865.
78. Muegge, I. Synergies of virtual screening approaches. Mini-Rev. Med. Chem., 2008, 8, 927-933.
79. Willett, P. Similarity methods in chemoinformatics. Annu. Rev. Inf. Sci. Technol., 2009, 43, 3-71.
80. Scior, T.; Bernard, P.; Medina-Franco, J.L.; Maggiora, G.M. Large compound databases for structure-activity relationships studies in drug discovery. Mini-Rev. Med. Chem., 2007, 7, 851-860.
81. Bender, A. Databases compound bioactivities go public. Nat. Chem. Biol., 2010, 6, 309-309.
82. López-Vallejo, F.; Nefzi, A.; Bender, A.; Owen, J.R.; Nabney, I.T.; Houghten, R.A.; Medina-Franco, J.L. Increased diversity of libraries from libraries: Chemoinformatic analysis of bis-diazacyclic libraries. Chem. Biol. Drug Des., 2011, 77, 328-342.
83. Wu, L.; Wang, X.; Xu, W.; Farzaneh, F.; Xu, R. The structure and pharmacological functions of coumarins and their derivatives. Curr. Med. Chem., 2009, 16, 4236-4260.
84. Yoo, J.; Medina-Franco, J.L. Chemoinformatic approaches for inhibitors of DNA methyltransferases: Comprehensive characterization of screening libraries. Computational Molecular Bioscience, 2011, 1, 7-16. Available at http://www.scirp.org/journal/PaperInformation.aspx?paperID=16496&publis hStatus=16492#abstract. 9